A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Sponsors Mylan
- 21 Sep 2018 Status changed from not yet recruiting to recruiting.
- 25 Jul 2018 Status changed from planning to not yet recruiting.
- 08 May 2018 According to a Momenta Pharmaceuticals media release, the company has announced IND acceptance by the FDA in January 2018, to start the trial in the first half of 2018.